advertisement

---

1 General aspects (0)   1.1 Epidemiology (4)   1.2 Population genetics (0)   1.3 Pathogenesis (9)   1.4 Quality of life (7)   1.5 Glaucomas as cause of blindness (7)   1.6 Prevention and screening (3) 2 Anatomical structures in glaucoma (0)   2.1 Conjunctiva (3)   2.2 Cornea (23)   2.3 Sclera (1)   2.4 Anterior chamber angle (7)   2.5 Meshwork (0)     2.5.1 Trabecular meshwork (18)     2.5.2 Schlemms canal (0)     2.5.3 Scleral outlet channels (1)   2.6 Aqueous humor dynamics (0)     2.6.1 Production (0)     2.6.2 Outflow (0)       2.6.2.1 Trabecular meshwork (4)       2.6.2.2 Uveoscleral (1)     2.6.3 Compostion (8)   2.7 Episcleral veins and venous pressure (0)   2.8 Iris (3)   2.9 Ciliary body (2)   2.10 Lens (2)   2.11 Vitreous body (2)   2.12 Choroid, peripapillary choroid, peripapillary atrophy (3)   2.13 Retina and retinal nerve fibre layer (43)   2.14 Optic disc (18)   2.15 Optic nerve (3)   2.16 Chiasma and retrochiasmal central nervous system (0)   2.17 Stem cells (0)   2.20 Other (1) 3 Laboratory methods (0)   3.1 Microscopy (1)   3.2 Electron microscopy (0)   3.3 Immunohistochemistry (7)   3.4 Molecular genetics (0)     3.4.1 Linkage studies (0)     3.4.2 Gene studies (20)   3.5 Molecular biology incl. SiRNA (19)   3.6 Cellular biology (40)   3.7 Biochemistry (9)   3.8 Pharmacology (27)   3.9 Pathophysiology (0)   3.10 Immunobiology (3)   3.11 Pharmacogenetics (0)   3.12 Proteomics (3)   3.13 In vivo imaging (0)     3.13.1 Laser Scanning (0)       3.13.1.1 Confocal Scanning Laser Ophthalmoscopy (2)       3.13.1.2 Confocal Scanning Laser Polarimetry (0)     3.13.2 Optical Coherence Tomography (0)       3.13.2.1 Anterior Segment (0)       3.13.2.2 Posterior Segment (0)     3.13.3 RGC Imaging (0)     3.13.4 Other (0)   3.20 Other (0) 4 Tissue culture of ocular cells (0) 5 Experimental glaucoma; animal models (0)   5.1 Rodent (16)   5.2 Primates (0)   5.3 Other (21) 6 Clinical examination methods (0)   6.1 Intraocular pressure measurement; factors affecting IOP (1)     6.1.1 Devices, techniques (12)     6.1.2 Fluctuation, circadian rhythms (12)     6.1.3 Factors affecting IOP (6)   6.2 Tonography, aqueous flow measurement (see also 2.6) (0)   6.3 Biomicroscopy (slitlamp) (0)     6.3.1 Anterior segment (0)     6.3.2 Posterior segment (0)   6.4 Gonioscopy (1)   6.5 Ophthalmoscopy (0)   6.6 Visual field examination and other visual function tests (1)     6.6.1 Conventional manual (1)     6.6.2 Automated (22)     6.6.3 Special methods (e.g. color, contrast, SWAP etc.) (14)   6.7 Electro-ophthalmodiagnosis (4)   6.8 Photography (0)     6.8.1 Anterior segment (3)     6.8.2 Posterior segment (6)   6.9 Computerized image analysis (1)     6.9.1 Laser scanning (0)       6.9.1.1 Confocal Scanning Laser Ophthalmoscopy (13)       6.9.1.2 Confocal Scanning Laser Polarimetry (12)     6.9.2 Optical coherence tomography (0)       6.9.2.1 Anterior (7)       6.9.2.2 Posterior (14)     6.9.5 Other (5)   6.10 Fluorescein (ICG) angiography (0)     6.10.1 Anterior segment (1)     6.10.2 Posterior segment (0)   6.11 Bloodflow measurements (24)   6.12 Ultrasonography and ultrasound biomicroscopy (14)   6.13 Provocative tests (1)   6.19 Telemedicine (1)   6.20 Progression (0)   6.30 Other (0) 8 Refractive errors in relation to glaucoma (0)   8.1 Myopia (2)   8.2 Hypermetropia (0)   8.3 Contact lenses (0)   8.4 Refractive surgical procedures (4)   8.5 Other (0) 9 Clinical forms of glaucomas (0)   9.1 Developmental glaucomas (0)     9.1.1 Congenital glaucoma, Buphthalmos (6)     9.1.2 Juvenile glaucoma (6)     9.1.3 Syndromes of Axenfeld, Rieger, Peters, aniridia (3)     9.1.4 Other (0)   9.2 Primary open angle glaucomas (0)     9.2.1 Ocular hypertension (9)     9.2.2 Other risk factors for glaucoma (3)     9.2.3 Open angle glaucoma with elevated IOP (7)     9.2.4 Normal pressure glaucoma (8)   9.3 Primary angle closure glaucomas (2)     9.3.1 Acute primary angle closure glaucoma (pupillary block) (11)     9.3.2 Chronic primary angle closure glaucoma (pupillary block) (2)     9.3.3 Plateau iris syndrome (2)     9.3.4 Primary angle closure suspect (1)     9.3.5 Primary angle closure (9)     9.3.10 Other (1)   9.4 Glaucomas associated with other ocular and systemic disorders (0)     9.4.1 Steroid-induced glaucoma (6)     9.4.2 Glaucomas associated with disorders of the cornea, conjunctiva, sclera (3)       9.4.2.1 Iridocorneal endothelial syndrome (ICE, incl. irisatrophy) (1)       9.4.2.2 Posterior polymorphous dystrophy (0)       9.4.2.3 Fuchs' endothelial dystrophy (0)       9.4.2.5 Other (4)     9.4.3 Glaucomas associated with disorders of the iris and ciliary body (0)       9.4.3.1 Pigmentary glaucoma (1)       9.4.3.5 Other (3)     9.4.4 Glaucomas associated with disorders of the lens (0)       9.4.4.1 Exfoliation syndrome (22)       9.4.4.2 Glaucomas associated with cataracts (4)       9.4.4.3 Glaucomas associated with lens dislocation (1)       9.4.4.5 Other (2)     9.4.5 Glaucomas associated with disorders of the retina, choroid and vitreous (1)       9.4.5.1 Neovascular glaucoma (5)       9.4.5.5 Other (9)     9.4.6 Glaucomas associated with inflammation, uveitis (10)     9.4.7 Glaucomas associated with ocular trauma (2)     9.4.8 Glaucomas associated with intraocular tumors (0)     9.4.9 Glaucomas associated with elevated episcleral venous pressure (1)       9.4.10 Glaucomas associated with hemorrhage (0)     9.4.11 Glaucomas following intraocular surgery (0)       9.4.11.1 Ciliary block (malignant) glaucoma (1)       9.4.11.2 Glaucomas in aphakia and pseudophakia (2)       9.4.11.3 Epithelial, fibrous, and endothelial proliferation (0)       9.4.11.4 Glaucomas associated with corneal surgery (0)       9.4.11.5 Glaucomas associated with vitreoretinal surgery (4)     9.4.15 Glaucoma in relation to systemic disease (21)     9.4.20 Other (0) 10 Differential diagnosis e.g. anterior and posterior ischemic optic neuropathy (6) 11 Medical treatment (0)   11.1 General management, indication (14)   11.2 Cholinergic drugs (3)   11.3 Adrenergic drugs (1)     11.3.1 Epinephrine (0)     11.3.2 Thymoxamine, dapiprazole (0)     11.3.3 Apraclonidine, brimonidine (6)     11.3.4 Betablocker (9)     11.3.5 Other (0)   11.4 Prostaglandins (27)   11.5 Carbonic anhydrase inhibitors (3)     11.5.1 Systemic (0)     11.5.2 Topical (5)   11.6 Osmotic treatment (0)   11.7 Treatment of bloodflow (0)   11.8 Neuroprotection (17)   11.9 Gene therapy (2)   11.13 Combination therapy (1)     11.13.1 Betablocker and pilocarpine (0)     11.13.2 Betablocker and carbon anhydrase inhibitor (3)     11.13.3 Betablocker and brimonidine (0)     11.13.4 Betablocker and prostaglandin (4)     11.13.5 Other (0)   11.14 Investigational drugs; pharmacological experiments (11)   11.15 Other drugs in relation to glaucoma (2)   11.16 Vehicles, delivery systems, pharmacokinetics, formulation (11)   11.17 Cooperation with medical therapy e.g. persistency, compliance, adherence (2)   11.20 Other (4) 12 Surgical treatment (0)   12.1 General management, indication (6)   12.2 Laser iridotomy (2)   12.3 Laser iridoplasty (1)   12.4 Laser trabeculoplasty and other laser treatment of the angle (4)   12.7 Surgical iridectomy (0)   12.8 Filtering surgery (2)     12.8.1 Without tube implant (7)     12.8.2 With tube implant or other drainage devices (10)     12.8.3 Non-perforating (8)     12.8.4 Using laser (1)     12.8.5 Other (0)     12.8.10 Woundhealing antifibrosis (8)     12.8.11 Complications, endophthalmitis (4)   12.9 Trabeculotomy, goniotomy (2)   12.10 Cyclodestruction (5)   12.11 Cyclodialysis (0)   12.12 Cataract extraction (1)     12.12.1 Intracapsular (0)     12.12.2 Extracapsular (0)     12.12.3 Phacoemulsification (9)   12.14 Combined cataract extraction and glaucoma surgery (1)     12.14.1 Intracapsular (0)     12.14.2 Extracapsular (0)     12.14.3 Phacoemulsification (9)   12.15 Capsulotomy (2)   12.16 Vitrectomy (3)   12.17 Anesthesia (2)   12.20 Other (1) 13 Therapeutic prognosis and outcome (0)   13.1 Prognostic factors (1)   13.2 Outcome (0)     13.2.1 IOP (3)     13.2.2 Visual field (0)       13.2.2.1 Progression (5)       13.2.2.2 Improvement (0)     13.2.3 Other (1) 14 Costing studies; pharmacoeconomics (12) 15 Miscellaneous (17)

---

Abstract #20413 Published in IGR 10-1

Protein carbonyl levels in the aqueous humour and serum of patients with pseudoexfoliation syndrome

Yaǧcı R; Ersöz I; Erdurmuş M; Gürel A; Duman S
Eye 2008; 22: 128-131

---

PURPOSE: Protein oxidation is an oxidative stress marker and the oxidation of proteins is analysed by measuring the carbonyl groups. Protein oxidation can have a role in the physiopathology of pseudoexfoliation (PEX) syndrome. The aim of this study was to investigate the protein oxidation in the aqueous humour and serum of cataract patients with and without PEX. METHODS: A multicenter study was carried out. Aqueous humour and serum samples were collected from patients who underwent routine cataract surgery. Patients were divided into PEX (n=29) and control (n=27) groups. Patients had no elevated intraocular pressure or glaucoma. Spectrophotometer was used to measure protein carbonyl (PC) levels in the samples. RESULTS: Mean PC concentration in the PEX aqueous (2.18±1.51 nmol/l) and serum (119.62±13.2 nmol/l) samples was significantly higher than that measured in the control aqueous (1.31±0.47 nmol/l) and serum (105.85±11.76 nmol/l) samples, respectively (P< 0.001). CONCLUSION: The increased PC levels in the aqueous humour and serum of PEX patients suggest that protein oxidation may play a role in the physiopathology of PEX.

Dr. R. Yaǧcı, Department of Ophthalmology, Medical School, Fatih University, Ankara, Turkey

---

Classification:

9.4.4.1 Exfoliation syndrome (Part of: 9 Clinical forms of glaucomas > 9.4 Glaucomas associated with other ocular and systemic disorders > 9.4.4 Glaucomas associated with disorders of the lens)
2.6.3 Compostion (Part of: 2 Anatomical structures in glaucoma > 2.6 Aqueous humor dynamics)
3.7 Biochemistry (Part of: 3 Laboratory methods)

---

• ← Previous
• Next →

---